표적 단백질 분해(TPD) 시장 규모, 점유율, 성장 분석 : 유형별, 치료 분야별, 투여 경로별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Global Targeted Protein Degradation Market size was valued at USD 646.02 Million in 2024 and is poised to grow from USD 826.26 Million in 2025 to USD 5916.74 Million by 2033, growing at a CAGR of 27.9% during the forecast period (2026-2033).

The market for Global Targeted Protein Degradation is gaining traction as an innovative drug development strategy that employs small molecules to specifically eliminate disease-related proteins. Key benefits of this approach include its broad applicability, allowing treatment of various conditions previously deemed "undruggable," such as certain cancers and genetic disorders. The selectivity offered by targeted protein degradation minimizes off-target effects, enhancing the therapeutic impact while reducing side effects. Additionally, treatments can demonstrate increased durability, maintaining efficacy longer than conventional drugs, which may lead to less frequent dosing and improved patient adherence. This novel mode of action paves the way for combination therapies, further broadening the therapeutic landscape and driving growth within the targeted protein degradation market segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Protein Degradation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Protein Degradation Market Segments Analysis

Global Targeted Protein Degradation Market is segmented by type, therapeutic area, route of administration, end use and region. Based on type, the market is segmented into degronimids, immunomodulatory drugs (IMIDS), proteolysis-targeting chimeric molecules (PROTACS), sudden acquired retinal degeneration syndrome (SARDS), selective estrogen receptor degraders (SERDS) and others. Based on therapeutic area, the market is segmented into inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders and others. Based on route of administration, the market is segmented into oral, intravenous and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospital & clinical laboratories and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is experiencing considerable growth driven by the increasing demand for more effective therapeutic options across various diseases. Conditions such as cancer, genetic disorders, and autoimmune disorders significantly affect patient well-being, highlighting the urgent need for treatments that target the root causes of these illnesses. Targeted protein degradation technology holds promise in selectively degrading disease-related proteins, thereby offering improved treatment efficacy with potentially fewer side effects. This innovative approach facilitates the creation of drugs that focus on harmful proteins while leaving healthy cells intact, minimizing adverse reactions and enhancing patient outcomes. Furthermore, this targeted mechanism presents solutions for challenging diseases previously deemed "undruggable," unlocking new avenues for drug development and providing renewed hope for patients with limited treatment options.

Restraints in the Global Targeted Protein Degradation Market

The targeted protein degradation market encounters significant challenges due to the inherent complexity of the field. This innovative approach necessitates an in-depth comprehension of protein structure and function, along with sophisticated drug design and development skills. The process of creating new therapies centered on targeted protein degradation is often intricate and lengthy, causing potential delays in advancements within the sector. Developers must thoroughly understand disease biology and the specific proteins involved to craft effective solutions. Additionally, the design of potent, selective, and stable molecules that can interact with the cellular degradation machinery is essential, demanding substantial investment in research and development.

Market Trends of the Global Targeted Protein Degradation Market

The Global Targeted Protein Degradation market is witnessing a significant trend towards the development of oral drug formulations, driven by the increasing demand for more patient-friendly treatment options. These oral therapies offer unparalleled convenience, allowing patients to manage their conditions without the need for frequent clinic visits or invasive procedures. Pharmaceutical companies are prioritizing research to create oral drugs that can effectively navigate the digestive system and maintain therapeutic efficacy through sustained release mechanisms. This shift not only enhances patient compliance, vital for treatment success, but also promises to transform patient care by facilitating more manageable and accessible therapeutic options for a variety of diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Targeted Protein Degradation Market Size by Type & CAGR (2026-2033)

• Market Overview
• Degronimids
• Immunomodulatory Drugs (IMIDS)
• Proteolysis-Targeting Chimeric Molecules (PROTACS)
• Sudden Acquired Retinal Degeneration Syndrome (SARDS)
• Selective Estrogen Receptor Degraders (SERDS)
• Others

Global Targeted Protein Degradation Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Inflammatory Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Others

Global Targeted Protein Degradation Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous
• Others

Global Targeted Protein Degradation Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Clinical Laboratories
• Others

Global Targeted Protein Degradation Market Size & CAGR (2026-2033)

• North America (Type, Therapeutic Area, Route of Administration, End Use)
  • US
  • Canada
• Europe (Type, Therapeutic Area, Route of Administration, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, Route of Administration, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, Route of Administration, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, Route of Administration, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Arvinas (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C4 Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foghorn Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (Johnson & Johnson) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations